Variation in statin prescription among veterans with HIV and known atherosclerotic cardiovascular disease.
CVD
Cardiovascular disease
HIV
Health care quality
Health services
Human immunodeficiency virus
Statin
Journal
American heart journal
ISSN: 1097-6744
Titre abrégé: Am Heart J
Pays: United States
ID NLM: 0370465
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
05
11
2021
revised:
12
03
2022
accepted:
14
03
2022
pubmed:
24
3
2022
medline:
31
5
2022
entrez:
23
3
2022
Statut:
ppublish
Résumé
People with HIV have increased atherosclerotic cardiovascular disease (ASCVD) risk, worse outcomes following incident ASCVD, and experience gaps in cardiovascular care, highlighting the need to improve delivery of preventive therapies in this population. Assess patient-level correlates and inter-facility variations in statin prescription among Veterans with HIV and known ASCVD. We studied Veterans with HIV and existing ASCVD, ie, coronary artery disease (CAD), ischemic cerebrovascular disease (ICVD), and peripheral arterial disease (PAD), who received care across 130 VA medical centers for the years 2018-2019. We assessed correlates of statin prescription using two-level hierarchical multivariable logistic regression. Median odds ratios (MORs) were used to quantify inter-facility variation in statin prescription. Nine thousand six hundred eight Veterans with HIV and known ASCVD (mean age 64.3 ± 8.9 years, 97% male, 48% Black) were included. Only 68% of the participants were prescribed any-statin. Substantially higher statin prescription was observed for those with diabetes (adjusted odds ratio [OR] = 2.3, 95% confidence interval [CI], 2.0-2.6), history of coronary revascularization (OR = 4.0, CI, 3.2-5.0), and receiving antiretroviral therapy (OR = 3.0, CI, 2.7-3.4). Blacks (OR = 0.7, CI, 0.6-0.9), those with non-coronary ASCVD, ie, ICVD and/or PAD only, (OR 0.53, 95% CI: 0.48-0.57), and those with history of illicit substance use (OR=0.7, CI, 0.6-0.9) were less likely to be prescribed statins. There was significant variation in statin prescription across VA facilities (10th, 90th centile: 55%, 78%), with an estimated 20% higher likelihood of difference in statin prescription practice for two clinically similar individuals treated at two comparable facilities (adjusted MOR = 1.21, CI, 1.18-1.24), and a greater variation observed for Blacks or those with non-coronary ASCVD or history of illicit drug use. In an analysis of large-scale VA data, we found suboptimal statin prescription and significant interfacility variation in statin prescription among Veterans with HIV and known ASCVD, particularly among Blacks and those with a history of non-coronary ASCVD.
Sections du résumé
BACKGROUND
People with HIV have increased atherosclerotic cardiovascular disease (ASCVD) risk, worse outcomes following incident ASCVD, and experience gaps in cardiovascular care, highlighting the need to improve delivery of preventive therapies in this population.
OBJECTIVE
Assess patient-level correlates and inter-facility variations in statin prescription among Veterans with HIV and known ASCVD.
METHODS
We studied Veterans with HIV and existing ASCVD, ie, coronary artery disease (CAD), ischemic cerebrovascular disease (ICVD), and peripheral arterial disease (PAD), who received care across 130 VA medical centers for the years 2018-2019. We assessed correlates of statin prescription using two-level hierarchical multivariable logistic regression. Median odds ratios (MORs) were used to quantify inter-facility variation in statin prescription.
RESULTS
Nine thousand six hundred eight Veterans with HIV and known ASCVD (mean age 64.3 ± 8.9 years, 97% male, 48% Black) were included. Only 68% of the participants were prescribed any-statin. Substantially higher statin prescription was observed for those with diabetes (adjusted odds ratio [OR] = 2.3, 95% confidence interval [CI], 2.0-2.6), history of coronary revascularization (OR = 4.0, CI, 3.2-5.0), and receiving antiretroviral therapy (OR = 3.0, CI, 2.7-3.4). Blacks (OR = 0.7, CI, 0.6-0.9), those with non-coronary ASCVD, ie, ICVD and/or PAD only, (OR 0.53, 95% CI: 0.48-0.57), and those with history of illicit substance use (OR=0.7, CI, 0.6-0.9) were less likely to be prescribed statins. There was significant variation in statin prescription across VA facilities (10th, 90th centile: 55%, 78%), with an estimated 20% higher likelihood of difference in statin prescription practice for two clinically similar individuals treated at two comparable facilities (adjusted MOR = 1.21, CI, 1.18-1.24), and a greater variation observed for Blacks or those with non-coronary ASCVD or history of illicit drug use.
CONCLUSION
In an analysis of large-scale VA data, we found suboptimal statin prescription and significant interfacility variation in statin prescription among Veterans with HIV and known ASCVD, particularly among Blacks and those with a history of non-coronary ASCVD.
Identifiants
pubmed: 35318028
pii: S0002-8703(22)00054-0
doi: 10.1016/j.ahj.2022.03.006
pmc: PMC9976623
mid: NIHMS1872632
pii:
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12-22Subventions
Organisme : HSRD VA
ID : C19 20-213
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI042853
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
Am J Manag Care. 2013 Apr 01;19(4):e133-9
pubmed: 23725451
Clin Infect Dis. 2016 Aug 1;63(3):407-13
pubmed: 27143663
Circ Cardiovasc Qual Outcomes. 2016 Nov;9(6):704-713
pubmed: 27756795
Prog Cardiovasc Dis. 2020 Mar - Apr;63(2):79-91
pubmed: 32199901
Trans Am Clin Climatol Assoc. 2018;129:140-154
pubmed: 30166708
Eur Heart J. 2013 Dec;34(46):3538-46
pubmed: 24126882
J Am Coll Cardiol. 2019 Jun 25;73(24):e285-e350
pubmed: 30423393
Am J Public Health. 2003 Oct;93(10):1728-33
pubmed: 14534229
Circulation. 2018 May 22;137(21):2203-2214
pubmed: 29444987
Am Heart J. 2017 Jan;183:91-101
pubmed: 27979047
J Am Heart Assoc. 2017 Nov 14;6(11):
pubmed: 29138182
Am J Health Syst Pharm. 2016 Apr 1;73(7):468-94
pubmed: 26892679
J Epidemiol Community Health. 2006 Apr;60(4):290-7
pubmed: 16537344
J Am Heart Assoc. 2018 Dec 18;7(24):e010345
pubmed: 30526249
Lancet. 2010 Nov 13;376(9753):1670-81
pubmed: 21067804
PLoS One. 2013;8(3):e52828
pubmed: 23469159
Lancet HIV. 2015 Feb;2(2):e52-63
pubmed: 26424461
JAMA Intern Med. 2013 Apr 22;173(8):614-22
pubmed: 23459863
BMC Infect Dis. 2018 Jun 5;18(1):258
pubmed: 29866059
Circulation. 2019 Jul 9;140(2):e98-e124
pubmed: 31154814
Br J Gen Pract. 2020 Jul 30;70(697):e525-e533
pubmed: 32601055
AIDS Patient Care STDS. 2017 Nov;31(11):447-454
pubmed: 29087746
JAMA Netw Open. 2020 Nov 2;3(11):e2025505
pubmed: 33216139
Cardiovasc Drugs Ther. 2020 Dec;34(6):745-754
pubmed: 32840709
JAMA. 2020 Jul 7;324(1):68-78
pubmed: 32633800
J Am Heart Assoc. 2021 Jan 5;10(1):e019533
pubmed: 33325243
N Engl J Med. 2020 Apr 9;382(15):1395-1407
pubmed: 32227755
J Gen Intern Med. 2009 Mar;24(3):334-40
pubmed: 19127386
JAMA Netw Open. 2020 Jun 1;3(6):e207954
pubmed: 32539152
Vasc Med. 2018 Jun;23(3):232-240
pubmed: 29600737
JAMA Cardiol. 2017 May 1;2(5):536-546
pubmed: 28384660
J Clin Transl Endocrinol. 2017 Feb 22;8:6-14
pubmed: 29067253